2019

1. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

   Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 208-230